{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:31:03Z","timestamp":1782307863236,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of venetoclax combined with intensive chemotherapy regimens in patients with relapsed or refractory acute myeloid leukemia (R\/R AML) through a systematic review and single\u2010arm meta\u2010analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search of PubMed, Embase, and Cochrane CENTRAL was conducted from inception to January 2025. Non\u2010randomized studies enrolling R\/R AML patients treated with venetoclax plus intensive chemotherapy were included. Pooled rates of complete remission (CR), composite complete remission (CRc), overall response rate (ORR), and adverse events were estimated using random\u2010effects models. Heterogeneity was assessed with I\n                      <jats:sup>2<\/jats:sup>\n                      statistics, and sensitivity and subgroup analyses were performed according to chemotherapy regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six retrospective studies comprising 235 patients were included. The pooled CR rate was 27.0% (95% CI, 9.18\u201357.50; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200984.6%), CRc rate was 51.45% (95% CI, 36.15\u201366.76; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200983.5%), and ORR was 63.79% (95% CI, 49.67\u201377.92; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200982.0%). Febrile neutropenia occurred in 71.38% and pneumonia in 23.6% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Venetoclax combined with intensive chemotherapy demonstrates meaningful antileukemic activity in R\/R AML, with an expected toxicity profile. Prospective trials are warranted to define its role relative to standard salvage therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70175","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:00:21Z","timestamp":1774486821000},"page":"88-99","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed\/Refractory Acute Myeloid Leukemia: A Systematic Review and Single\u2010Arm Meta\u2010Analysis"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-0019","authenticated-orcid":false,"given":"Marcos Niedziewski","family":"Goularte","sequence":"first","affiliation":[{"name":"Universidade da Regi\u00e3o de Joinville\u2010UNIVILLE  SC Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7200-1913","authenticated-orcid":false,"given":"Mariany Hatori","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Universidade da Regi\u00e3o de Joinville\u2010UNIVILLE  SC Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-7167","authenticated-orcid":false,"given":"Marcelo Pitombeira","family":"de Lacerda","sequence":"additional","affiliation":[{"name":"Universidade da Regi\u00e3o de Joinville\u2010UNIVILLE  SC Brazil"},{"name":"Departamento de Hematologia e Oncologia Hospital Municipal S\u00e3o Jos\u00e9  SC Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000561"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201008"},{"issue":"4","key":"e_1_2_13_4_1","first-page":"124","article-title":"Original Article Outcomes of Patients With Relapsed or Refractory Acute Myeloid Leukemia: A Population\u2010Based Real\u2010World Study","volume":"10","author":"Brandwein J. M.","year":"2020","journal-title":"American Journal of Blood Research"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020549"},{"key":"e_1_2_13_7_1","first-page":"72","article-title":"Fludarabine, Cytarabine, and Idarubicin With or Without Venetoclax in Patients With Relapsed\/Refractory Acute Myeloid Leukemia","volume":"109","author":"Shahswar R.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14302"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010024\u201013000\u20103"},{"key":"e_1_2_13_10_1","unstructured":"\u201cVenetoclax as Monotherapy and in Combination With Hypomethylating Agents or Low Dose Cytarabine in Relapsed and Treatment Refractory Acute Myeloid Leukemia: A Systematic Review and Meta\u2010Analysis \u201d."},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107368"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_13_13_1","unstructured":"\u201cCochrane Handbook for Systematic Reviews of Interventions (Current Version) | Cochrane \u201dhttps:\/\/www.cochrane.org\/authors\/handbooks\u2010and\u2010manuals\/handbook\/current."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223872"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02531-8"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.284962"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201000982\u20103"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.002"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864\u2010020\u201000765\u20105"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0624-2"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70175","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:53:55Z","timestamp":1781873635000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/ejh.70175"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70175","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2025-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}